©The Author(s) 2020.
World J Clin Oncol. Aug 24, 2020; 11(8): 589-605
Published online Aug 24, 2020. doi: 10.5306/wjco.v11.i8.589
Published online Aug 24, 2020. doi: 10.5306/wjco.v11.i8.589
Table 3 Clinical study of combined molecular targeted therapy based on sorafenib treatment for hepatocellular carcinoma
| Drug + Sorafenib | Phase | Ref./ClinicalTrials.gov identifier |
| VEGF inhibitors | ||
| Bevacizumab | I/II | NCT00867321 |
| Lenvatinib | I/II (HCC) | NCT01271504 |
| mTOR inhibitor | ||
| Everolimus (RAD001) | II | NCT01005199 |
| I/II | [154] | |
| Temsirolimus | I/II | NCT01335074, NCT01687673, NCT01008917 |
| HDAC inhibitors | ||
| Resminostat | II (Advanced HCC) | NCT00943449 |
| Panobinostat | I (HCC) | NCT00823290 |
| Anti-GPC3 antibody | ||
| GC33 | I | NCT00976170 |
| MEK1 inhibitor | ||
| Selumetinib (AZD6244) | I/II | NCT01029418 |
| HGFR inhibitor | ||
| Tivantinib (ARQ197) | I | NCT00827177 |
| TNF-α secretion inhibitor | ||
| Lenalidomide | I | NCT01348503 |
| TRAIL receptor 1 antibody | ||
| Mapatumumab | I/II | NCT00712855, NCT01258608 |
- Citation: Chow AKM, Yau SWL, Ng L. Novel molecular targets in hepatocellular carcinoma. World J Clin Oncol 2020; 11(8): 589-605
- URL: https://www.wjgnet.com/2218-4333/full/v11/i8/589.htm
- DOI: https://dx.doi.org/10.5306/wjco.v11.i8.589